膵臓疾患と治療

膵臓疾患と治療
オープンアクセス

ISSN: 2165-7092

概要

Non-alcoholic Fatty Liver Disease and Covid-19

Sezer Akbulut, Kivanc Derya Peker*, Kemal Dolay, Gokhan Tolga Adas

Introductory proof from China recommends that most weak subjects to COVID-19 disease experience the ill effects of previous sickness, including metabolic irregularities. The pandemic attributes and high-lethality pace of COVID-19 contamination have raised worries about collaborations between infection pathobiology and segments of the metabolic condition. NAFLD can assume a job in the result of COVID-19 ailment because of incessant relationship with comorbidities. Beginning confirmations propose that expanded liver fibrosis in NAFLD might influence COVID-19 result. Furthermore, long haul observing of post-COVID-19 NAFLD patients is prudent, to report further disintegration of liver harm. Further examinations are needed in this field.

免責事項: この要約は人工知能ツールを使用して翻訳されたものであり、まだレビューまたは検証されていません。
Top